 |
D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate |
|---|---|
| Trade Name | |
| Orphan Indication | Melanoma, stages IIb through IV |
| USA Market Approval | USA |
| USA Designation Date | 2009-03-19 00:00:00 |
| Sponsor | Thallion Pharmaceuticals, Inc.;7150 Alexander-Fleming; |
